Live news related to SANOFI stock (FR0000120578): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
Sanofi announced that the American Food and Drug Administration has extended the review period for its approval application for Sarclisa in a subcutan…
The European Commission has approved Dupixent (dupilumab) for the treatment of moderate to severe spontaneous chronic urticaria in children aged two t…
Sanofi announces that its drug candidate lunsekimig has met its primary and key secondary endpoints in two Phase 2 studies for moderate to severe asth…
The European Commission has granted conditional marketing authorization for Rezurock (belumosudil) for the treatment of chronic graft-versus-host dise…
On Friday, March 28, Sanofi unveiled positive results from three Phase 3 studies assessing amlitelimab, a monoclonal antibody, for the treatment of mo…
Sanofi announces the release of its 'Q1 2026 Briefing Document' aimed at assisting investors with financial modeling. This quarterly document addresse…
Dupixent (dupilumab), jointly developed by Sanofi and Regeneron, has been approved in Japan for the treatment of moderate to severe bullous pemphigoid…
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to venglustat, an experimental oral glucosylceramide synthase…
Sanofi's Board of Directors has proposed the appointment of Christel Heydemann as an independent director, which will be submitted for shareholder app…
Sanofi and Regeneron announce the FDA approval of Dupixent (dupilumab) for treating allergic fungal rhinosinusitis in adults and children aged 6 years…
